Largest TB Vaccine Trial in Decades Finds VPM1002 Halves Extrapulmonary Risk but Falls Short of Broad Protection
Phase 3 PreVenTB trial of 12,717 people across India shows VPM1002 cuts extrapulmonary tuberculosis by 50%, but neither candidate prevents pulmonary TB or latent infection.
4 min read5 sources